Restenosis after stent implantation is mainly caused by neointimal proliferation through the stent struts. Experimental studies indicate a marked activation of inflammatory cells at the site of stent struts, which are likely to play a key role in the process of neointimal proliferation and restenosis. Coronary stenting is a strong inflammatory stimulus and the acute systemic inflammatory response to local inflammation produced by coronary stenting is highly individual and predicts restenosis and event-free survival. The benefit of anti-inflammatory therapy during the periprocedural period and long-term follow-up is dependent on the inflammatory status. Measurement of cytokine and acute phase proteins, such as C-reactive protein, may be important to identify high-risk subjects and develop specific treatment tailored to the individual patient. (C) 2004 Lippincott Williams Wilkins.

Versaci, F., Gaspardone, A. (2004). Prevention of restenosis after stenting: the emerging role of inflammation. CORONARY ARTERY DISEASE, 15(6), 307-311 [10.1097/00019501-200409000-00002].

Prevention of restenosis after stenting: the emerging role of inflammation

Versaci, Francesco
Writing – Review & Editing
;
Gaspardone, Achille
Membro del Collaboration Group
2004-09-01

Abstract

Restenosis after stent implantation is mainly caused by neointimal proliferation through the stent struts. Experimental studies indicate a marked activation of inflammatory cells at the site of stent struts, which are likely to play a key role in the process of neointimal proliferation and restenosis. Coronary stenting is a strong inflammatory stimulus and the acute systemic inflammatory response to local inflammation produced by coronary stenting is highly individual and predicts restenosis and event-free survival. The benefit of anti-inflammatory therapy during the periprocedural period and long-term follow-up is dependent on the inflammatory status. Measurement of cytokine and acute phase proteins, such as C-reactive protein, may be important to identify high-risk subjects and develop specific treatment tailored to the individual patient. (C) 2004 Lippincott Williams Wilkins.
set-2004
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/06 - ONCOLOGIA MEDICA
English
Con Impact Factor ISI
inflammation
restenosis
stent
Acute-Phase Proteins
Anti-Inflammatory Agents
Coronary Restenosis
Cytokines
Humans
Inflammation
Stents
Tunica Intima
Vascular Diseases
Versaci, F., Gaspardone, A. (2004). Prevention of restenosis after stenting: the emerging role of inflammation. CORONARY ARTERY DISEASE, 15(6), 307-311 [10.1097/00019501-200409000-00002].
Versaci, F; Gaspardone, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Versaci_F_CorArtDis_2004 (1).pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 100.1 kB
Formato Adobe PDF
100.1 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/253230
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 39
social impact